Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer | NEJM The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patient...

New in NEJM: Phase 1 data on setigrasib, a first‑in‑class #KRAS G12D degrader, showed encouraging early activity in NSCLC and #PancreaticCancer, with a manageable safety profile. Proud to see #SCRI's Drs. Pelster & Wang contribute to this study.
www.nejm.org/doi/full/10....

On #DoctorsDay, we celebrate the physicians across #SCRI who are driving innovation, advancing clinical research, and putting patients first every day.
Your leadership, curiosity, and commitment are shaping the future of cancer care. Thank you for all you do.
#PhysicianLeadership #ClinicalTrials

Emerging Strategies in Prostate Cancer: Molecular Glues and T-Cell Engagers | CancerNetwork Benjamin Garmezy, MD, discussed the potential of a GSPT1 molecular glue degrader and a trispecific T-cell engager in treating select prostate cancers.

🧬 Dr. Benjamin Garmezy discusses emerging prostate cancer strategies—highlighting molecular glues & T‑cell engagers—in a new CancerNetwork interview.
🔗 www.cancernetwork.com/view/emergin...
#ProstateCancer #Oncology #PrecisionMedicine #SCRI

Let Me Help: Learning more about colorectal cancer March is Colorectal Cancer Awareness Month. Colorectal cancer is now the number one cause of cancer death in adults under 50, with cases rising 1% annually in this group.

Dr. Meredith Pelster of #SCRIOncologyPartners joined #NewsChannel5’s Let Me Help to discuss colorectal cancer and the importance of early screening. 👏
Watch the segment:
www.newschannel5.com/news/let-me-...

Scrip Asks... What Does 2026 Hold For Biopharma? Part 4: R&D Innovation Enthusiastic predictions from industry leaders for ongoing progress in obesity, oncology, immunology, neuroscience and more were supported by optimism for the potential of AI and other technological a...

In a new Scrip Asks, SCRI’s David Spigel, MD, discusses what 2026 holds for biopharma in oncology R&D and the push to operationalize complex therapies.

insights.citeline.com/scrip/scrip-...

#Oncology #Biopharma #RAndD #CancerResearch #ClinicalResearch #Innovation

As New Leaders Rise at SCRI, the Mission Remains: Bringing Clinical Trials Where Patients Live | AJMC New leaders of the Sarah Cannon Research Institute discuss its mission and priorities amid a changing landscape in community oncology.

As SCRI enters a new chapter, Drs. Spigel, Johnson, Hamilton & Subbiah share how scientific momentum is making community‑based research more important than ever.
www.ajmc.com/view/as-new-...
#ClinicalResearch

Atebimetinib Signals a Potential Shift in First-Line Pancreatic Cancer Outcomes | Pharmacy Times Experts discuss groundbreaking data on pancreatic cancer treatment, revealing a 64% survival rate and its potential to transform patient care and outcomes.

SCRI and SCRI Oncology expert, Dr. Meredith Pelster joined Pharmacy Times to discuss emerging data that could meaningfully change the treatment landscape for pancreatic cancer. Watch below to learn more:
www.pharmacytimes.com/view/atebime...
#PancreaticCancer #SCRI #OncologyResearch

Tukysa Makes Waves as Firstline Maintenance in HER2+ Breast Cancer | CURE Dr. Erika Hamilton sat down for an interview with CURE’s editor-in-chief, Dr. Joshua K. Sabari.

Dr. Erika Hamilton, #SCRI's CDO of Late Phase, as well as Director of Breast Cancer Research, sat down with CURE Today to discuss thenHER2CLIMB-05 trial. Read how this trial is making waves for people facing HER2-positive metastatic breast cancer.

www.curetoday.com/view/tukysa-...

Let Me Help: Can AI personalize my cancer treatment Dr. David Spigel is a medical oncologist at SCRI Oncology Partners in Nashville and President and Chief Medical Officer for Sarah Cannon Research Institute.

AI is revolutionizing cancer care. Dr. David Spigel, President & CMO at Sarah Cannon Research Institute, shares how personalized treatments and clinical trials are evolving.
Read the NewsChannel5 feature: www.newschannel5.com/news/let-me-...
#CancerResearch #AIinHealthcare

MorningSun trial shows SC mosunetuzumab is effective & well-tolerated for elderly or CIT-ineligible #DLBCL patients. Featuring SCRI’s Dr. Jeff Sharman:
www.hmpgloballearningnetwork.com/site/onc/new... #ASH25 #InnovationInOncology #SCRI

Congrats to our SCRI team for powering 100 abstracts & 50+ investigator-led presentations across hematologic diseases.
Patients remain at the center of all we do—here’s to driving impact beyond Orlando!
#SCRI

HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer PurposeThe HER2CLIMB-05 study (ClinicalTrials.gov identifier: NCT05132582) is investigating the efficacy and safety of adding tucatinib to trastuzumab and pertuzumab as first-line (1L) maintenance the...

We’re proud to share Dr. Erika Hamilton's latest publication in Journal of Clinical Oncology: #HER2CLIMB05, a Phase 3 study evaluating tucatinib in combo w/trastuzumab + pertuzumab as first-line maintenance therapy for HER2+ #metastaticbreastcancer.
ascopubs.org/doi/10.1200/...

Didn’t have a chance to meet our experts at #ASH25 booth 1580? Learn from them during their presentations today!
View the schedule: scriash2025.com

Meet #SCRI experts at #ASH25. Visit booth 1580 and view our full schedule: uberflip.scri.com/i/1541695-me...?

Dr. Burke takes the #ASH25 stage to answer the question: How Can Community-Based and Academic Hematologists Foster Clinical Trial Participation as Part of Patient Care?

Dr. Frangoul presents first results of exagamglogene autotemcel in children aged 5–11 with transfusion‑dependent β‑thalassemia or #SCD with recurrent severe VOCs.

A major moment for pediatric gene‑edited therapy research. #ASH25

🔬 Featured at #ASH25
Dr. Burke presented new Phase II MorningSun data on fixed‑duration subcutaneous mosunetuzumab with maintenance therapy for previously untreated high‑tumor‑burden follicular #lymphoma (HTB FL).

SCRI expert, Dr. Hans Lee serves as session chair during “#MultipleMyeloma: Pharmacologic Therapies: Advances in Treatment Strategies for Relapsed/Refractory Multiple Myeloma.” #ASH25

From AGAVE‑201, Dr. Farhadfar reports that switching to axatilimab 0.6 mg/kg Q4W was safe, feasible, and showed no new signals vs 0.3 mg/kg Q2W. Patients remained on therapy long‑term (median 1.7 y), with 84% continuing—suggesting ongoing benefit. #ASH25

Hematology is evolving fast, and SCRI experts are leading the way. Ahead of #ASH25, explore 5 trends shaping research and collaboration this year.
Read more: www.scri.com/news/sarah-c...
#SCRI #ASH25 #Hematology #Oncology

Sarah Cannon Research Institute will present 100 abstracts at #ASH25, marking our largest presence yet. 50+ investigators will share breakthroughs in blood cancers & disorders. Learn more: www.scri.com/news/sarah-c...

Mike: A Story of Hope & The Power of Clinical Trials YouTube video by Sarah Cannon Research Institute

Mike’s cancer journey shows the power of research + compassionate care. At SCRI, he found hope through clinical trials and unwavering support.
Watch his story: www.youtube.com/watch?v=29KR...
#CancerCare #ClinicalTrials #PatientStories

SCRI's Dr. Erika Hamilton shares updates in HER2+ breast cancer and explains how T-DXd is moving into curative settings, with DESTINY-Breast11 & 05 trials showing:
✅ 83% pCR rate
✅ Anthracycline-sparing
✅ Better disease-free survival
www.medpagetoday.com/meetingcover...
#ESMO25 #BreastCancer

We’re expanding our collaboration with @bmsnews to accelerate cancer research and broaden access to clinical trials through SCRI’s Accelero model.
Read more: www.scri.com/news/sarah-c...
#CancerResearch #ClinicalTrials

November is #LungCancerAwarenessMonth.
#SCRI's Dr. Melissa Johnson joined NewsChannel 5 to discuss how early detection and clinical trials are transforming lung cancer care. From low-dose CT scans to bispecifics, the future of treatment is here.
www.newschannel5.com/news/let-me-...

Tucatinib Regimen Improves PFS in HER2+ Metastatic Breast Cancer | CancerNetwork The safety profile of tucatinib plus trastuzumab and pertuzumab was consistent with the established profiles of each individual agent.

New data from HER2CLIMB-05: Tucatinib added to first-line maintenance therapy improves PFS in HER2+ metastatic breast cancer.
Dr. Erika Hamilton of SCRI shares insights on this promising approach.
Full Cancer Network story:
www.cancernetwork.com/view/tucatin...
#Oncology #BreastCancer #HER2CLIMB05

Journalist Who Discovered She Had Breast Cancer After Filming Mammogram Segment Shares Her Story Journalist Who Discovered She Had Breast Cancer After Filming Mammogram Segment Shares Her Story

Journalist Amy Robach opens up about discovering breast cancer after a filmed mammogram. SCRI’s Dr. Erika Hamilton shares expert tips on risk and prevention on the Drew Barrymore Show.
Watch here: www.thedrewbarrymoreshow.com/videos/journ...
#BreastCancerAwareness #SCRIExperts

Stage 1 Testicular Cancer: A Patient Education Overview | CURE From diagnosis to treatment, here is what patients need to know about stage 1 testicular cancer.

SCRI expert Dr. Ben Garmezy shares insights on testicular cancer diagnosis, treatment choices, and patient education in this CURE Today feature.
Read more:
www.curetoday.com/view/stage-1...
#CancerEducation #TesticularCancer #SCRI

Long-Term Data for PHAROS Show Half of Treatment-Naïve Patients Receiving Encorafenib Plus Binimetinib Alive at 4 Years | AJMC A mini oral session at ESMO of targeted therapy in non-small cell lung cancer included treatments that showed effectiveness in brain metastases.

PHAROS trial update: Half of treatment-naïve patients with BRAF V600E–mutant NSCLC treated with encorafenib + binimetinib are alive at 4 years.
Shoutout to Dr. Melissa Johnson for her leadership in advancing targeted therapy!
🔗 www.ajmc.com/view/long-te...
#CancerCare #Oncology #TargetedTherapy

Experts Highlight AI, Innovation, and Collaboration as Key PCOC Takeaways | AJMC Five experts share their key takeaways from Patient-Centered Oncology Care® (PCOC) 2025, highlighting AI integration and collaboration to improve care.

The future of oncology is here: AI-powered decisions, precision medicine, and collaborative care models. At #PCOC2025, experts—including Dr. Vivek Subbiah—explored how these innovations will improve patient outcomes.

🔗 www.ajmc.com/view/experts...
#HealthcareInnovation #Oncology #AI